Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04679012 · ClinicalTrials.gov registry record · Phase 2
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
A Phase 2 study of Chronic Lymphocytic Leukemia and Richter Syndrome, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 4
- Study locations
NCT04679012: Recruiting Phase 2 study of Chronic Lymphocytic Leukemia and Richter Syndrome, sponsored by Weill Medical College of Cornell University.
NCT04679012 is a Phase 2 study of Chronic Lymphocytic Leukemia and Richter Syndrome that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 20 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04679012, a Phase 2 study of Chronic Lymphocytic Leukemia and Richter Syndrome, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study evaluates the effectiveness and safety of Polatuzumab vedotin plus infusional chemoimmunotherapy containing rituximab, etoposide, prednisone, cyclophosphamide and hydroxydaunorubicin. This is a single arm study. Enrolled patients will receive up to six cycles (21-day cycles) of therapy. While on study, subjects will be monitored weekly until end of treatment, then followed for 52 weeks or until disease progression or discontinuation due to toxicity or death. After completion of the 52-week follow-up/End of study visit, Subjects will be followed for an additional 104 week period, with an assessment occurring every 12 weeks to evaluate survival outcomes and next line of treatments only.
Primary Outcome
Percentage of subjects who achieve CMR/CR on study.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Rituximab
- DRUG Etoposide
- DRUG Prednisone
- DRUG Polatuzumab Vedotin
Study Locations (4)
New York
- Mount Sinai- Icahn School of Medicine - New York
- Columbia University Medical Center - New York
- Weill Cornell Medicine - New York
Ohio
- Ohio state University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-09-24 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
What NCT04679012 shows while recruiting
NCT04679012 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04679012 reports a single indexed study location in New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT04679012 about?
NCT04679012 is a clinical study titled "Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation". This study evaluates the effectiveness and safety of Polatuzumab vedotin plus infusional chemoimmunotherapy containing rituximab, etoposide, prednisone, cyclophosphamide and hydroxydaunorubicin. This is a single arm study. Enrolled patients will receive up to six cycles (21-day cycles) of therapy. W...
What is the current status of trial NCT04679012?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2021-09-24. Estimated completion is 2027-09.
What conditions does trial NCT04679012 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Richter Syndrome.
What interventions are being tested in trial NCT04679012?
The interventions under investigation include: Cyclophosphamide (DRUG), Rituximab (DRUG), Etoposide (DRUG), Prednisone (DRUG), Polatuzumab Vedotin (DRUG).
Who is sponsoring clinical trial NCT04679012?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04679012 being conducted?
This trial has 4 study locations across New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04679012's enrollment target sits among peer trials
20 163rd of 187 higher than 24 of 187 other Chronic Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RECRUITING · Phase 2
-
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
RECRUITING · Phase 2
-
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
RECRUITING · Phase 2
-
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
RECRUITING · Phase 2
-
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI